Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push
DexCom, Inc. (NASDAQ:DXCM) ranks among the best fundamental stocks to buy according to hedge funds. Oppenheimer reaffirmed its $95 price target and Outperform rating for DexCom, Inc.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 623,335 | $54,410,886 | +20% | 1.06% |
| 2. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 50,872 | $4,440,617 | +11% | 1.9% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | $1,250,250.00 | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | $496,100.00 | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | $1,085,000.00 | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | $10,369.00 | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | $10,340.00 | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.03 | 8 | $688.24 | 53,871 | 2025-07-15 | Filing | |
| $85.17 | 2,742 | $233,528.46 | 53,879 | 2025-07-15 | Filing | |
| $86.03 | 500 | $43,015.00 | 94,602 | 2025-07-15 | Filing | |
| $85.06 | 1,466 | $124,697.96 | 108,155 | 2025-06-26 | Filing | |
| $83.13 | 2,750 | $228,604.75 | 56,621 | 2025-06-16 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,208,255 | $105,468,579 | 0.16% | |
| 2. | 1,052,110 | $91,838,682 | 0.63% | |
| 3. | 886,382 | $77,372,293 | 1.91% | |
| 4. | 345,590 | $30,166,552 | 1.33% | |
| 5. | 269,748 | $23,546,284 | 0.43% |
News See All
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating
DexCom, a global leader in glucose biosensing systems, stands out for its innovative continuous glucose monitoring (CGM) technology.
Billionaire Ken Griffin's 10 Midcap Stock Picks with Huge Upside Potential
Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.
DexCom, Inc. (DXCM): A Bull Case Theory
We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.
11 Best Medical Device Stocks to Buy Now
On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community.
DexCom, Inc. (NASDAQ:DXCM) Q1 2025 Earnings Call Transcript
Operator: Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.
DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns
Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here.
10 Best Diabetes Stocks To Buy According to Billionaires
The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income countries.
10 Best Growth Stocks Under $100 to Buy Now
Growth stocks are shares of companies which are expected to grow their revenue and earnings at a faster rate than the market average.
Billionaire Hedge Funds
